2C-T-7

Use and effects

In his book PiHKAL (Phenethylamines I Have Known and Loved), Alexander Shulgin lists 2C-T-7's dose range as 10 to 30mg orally and its duration as 8 to 15hours. It produces psychedelic effects. In PiHKAL, Shulgin records that the hallucinations it produces are unique, and that the chemical may cause muscle tension and an altered vocal quality. Shulgin rated it as one of the "magical half-dozen" most important psychedelic phenethylamines, together with mescaline, 2C-B, and 2C-T-2.

Interactions

2C-T-7 is metabolized by the monoamine oxidase (MAO) enzymes MAO-A and MAO-B. Monoamine oxidase inhibitors (MAOIs) such as phenelzine, tranylcypromine, moclobemide, and selegiline may potentiate the effects of 2C-T-7. This may result in overdose and serious toxicity.

Toxicity and deaths

There have been at least three reported deaths related to 2C-T-7 use as of August 2007, mainly at insufflated (snorted) doses of 30 mg or more. In the fall of 2000, a young healthy male died following insufflation of an excessive amount of 2C-T-7. Two additional deaths reported in April 2001 have been linked to 2C-T-7. These two deaths were reported by the DEA as being the result of the co-abuse of 2C-T-7 with MDMA.

In January 2002, Rolling Stone published an article about 2C-T-7 entitled "The New (legal) Killer Drug". Although the article suggested that the drug was legal, the legal status of 2C-T-7 was ambiguous at the time due to the United States' Federal Analogue Act. A detailed response on the website disinfo.com challenged the accuracy of much of the reporting in the aforementioned Rolling Stone article. 2C-T-7 has since been officially made illegal and declared a schedule 1 substance in the United States.

The Partnership for a Drug-Free America reported in 2006 that 2C-T-7 can be lethal even in small doses; however, they provide no source for their claim and of the three known deaths (as of August 2007) of 2C-T-7 intoxicated individuals, all involved either uncommonly large insufflated doses or the concomitant ingestion of other stimulants such as ephedrine and/or MDMA.

All of the three aforementioned known deaths of individuals under the influence of 2C-T-7 occurred in those known to be either intoxicated with other stimulants such as ephedrine or MDMA (which are known to be potentially lethal in certain situations or at excessive doses) or after the individual insufflated an amount of 2C-T-7 much greater than necessary to induce the full range of effects typically sought after by users of the drug; for example, the reported 35 mg insufflated dose taken by the individual who died in the fall of 2000. This reported dose was characterized as "excessive" by the United States DEA.

Pharmacology

Pharmacodynamics

2C-T-7 is a serotonin 5-HT2A receptor agonist, among other interactions. The mechanism that produces the psychedelic effects of 2C-T-7 is most likely to result from serotonin 5-HT2A receptor agonism in the brain, a mechanism of action shared by most currently-known hallucinogenic tryptamines and phenethylamines. 2C-T-7 has structural and pharmacodynamic properties similar to those of 2C-T-2.

Chemistry

Synthesis

The chemical synthesis of 2C-T-7 has been described.

History

2C-T-7 was first described in the scientific literature by Myron Stolaroff by 1990. It was developed by Alexander Shulgin and Peyton Jacob III. Subsequently, 2C-T-7 was described in greater detail by Shulgin and colleagues in 1991.

Up until Operation Web Tryp and three deaths, two of which involved the use of other drugs in addition to 2C-T-7, and one which involved an excessive insufflated dose, 2C-T-7 was sold commercially in Dutch and Japanese smartshops and online.

Society and culture

Legal status

Around the year 2000, 2C-T-7 began to change from an obscure chemical to a drug used at parties and clubs in North America and Europe as it became available through a number of grey-market commercial vendors. This aroused the attention of the authorities, and many countries have since scheduled the chemical.

Australia

In Australia, 2C-T-2 and 2C-T-7 are covered by the country's analogue drug laws.

Canada

As of October 31, 2016, 2C-T-7 is a controlled substance (Schedule III) in Canada.

China

As of October 2015 2C-T-7 is a controlled substance in China.

Finland

2C-T-7 is scheduled in the "government decree on substances, preparations and plants considered to be narcotic drugs".

Germany

2C-T-7 is scheduled in Germany. (BTMG)

Netherlands

The Netherlands was the first country in the world to ban 2C-T-7, after being sold in smartshops for a short period. After 2C-T-2 was first banned, 2C-T-7 quickly appeared on the market, but was soon banned as well. 2C-T-7 is a list I drug of the Opium Law.

Sweden

Schedule I in Sweden. 2C-T-7 was first classified as "health hazard" under the act Lagen om förbud mot vissa hälsofarliga varor (translated Act on the Prohibition of Certain Goods Dangerous to Health) as of April 1, 1999, under SFS 1999:58 that made it illegal to sell or possess.

United Kingdom

In 1999, Alexander Shulgin was sent a copy of a letter from the British Home Office to several of its administrative associates that in effect placed all compounds listed in PiHKAL into Class A.

United States

On September 20, 2002, 2C-T-7 was classified as a Schedule I substance in the United States by an emergency ruling by the DEA. On March 18, 2004, the DEA published a Final Rule in the Federal Register permanently placing 2C-T-7 in Schedule I. (69 FR 12794)

As of April 2024, law enforcement have encountered 2C-T-7 in 16 states, with the highest number of encounters being in Florida. Purchases made over the internet are believed by the DEA to be the most common source by which users of the drug acquire it in the United States, and one laboratory manufacturing the drug was discovered by police in Las Vegas, Nevada.

References

References

1. "PIHKAL #43".
2. (2000). "An Amateur Qualitative Study of 48 2C-T-7 Subjective Bioassays". Bulletin of the Multidisciplinary Association for Psychedelic Studies MAPS.
3. (2001-02-06). "Erowid 2C-T-7 Vault: Sulfurous Samadhi: Stolaroff's & Well's Study".
4. (June 28, 2001). "2C-T-7". Centre for Cognitive Liberty and Ethics (COLE).
5. (June 2013). "2C or not 2C: phenethylamine designer drug review". Journal of Medical Toxicology.
6. (January 2007). "Identification of monoamine oxidase and cytochrome P450 isoenzymes involved in the deamination of phenethylamine-derived designer drugs (2C-series)". Biochemical Pharmacology.
7. (January 2024). "Drug-drug interactions involving classic psychedelics: A systematic review". Journal of Psychopharmacology.
8. (October 2003). "Postmortem identification and quantitation of 2,5-dimethoxy-4-n-propylthiophenethylamine using GC-MSD and GC-NPD". Journal of Analytical Toxicology.
9. (1 May 2002). "A psychedelic summer". East Bay Express.
10. "2,5-dimethoxy-4-(n)-propylthiophenethylamine". Office of Diversion Control, Drug Enforcement Administration, U.S. Department of Justice.
11. "The New (Legal) Killer Drug". ''[[Rolling Stone]]'', January 10, 2002, issue 888: 44–49.
12. 21 USC §813
13. (2002). "The new (hip) drug hysteria: a journey into rolling stone's abandonment of journalistic ethics". Disinformation.
14. "2C-B, 2C-T-7".
15. (May 1972). "Symposium: behavior modification by drugs. I. Pharmacology of the amphetamines". Pediatrics.
16. (10 May 2025). "Kᵢ Database".
17. (December 2015). "Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs)". Neuropharmacology.
18. (May 2018). "Monoamine receptor interaction profiles of 4-thio-substituted phenethylamines (2C-T drugs)". Neuropharmacology.
19. (October 2020). "In vitro structure-activity relationship determination of 30 psychedelic new psychoactive substances by means of β-arrestin 2 recruitment to the serotonin 2A receptor". Archives of Toxicology.
20. (February 2019). "Interactions of phenethylamine-derived psychoactive substances of the 2C-series with human monoamine oxidases". Drug Testing and Analysis.
21. (April 2016). "In Vitro Characterization of Psychoactive Substances at Rat, Mouse, and Human Trace Amine-Associated Receptor 1". The Journal of Pharmacology and Experimental Therapeutics.
22. (January 2008). "The behavioral pharmacology of hallucinogens". Biochemical Pharmacology.
23. (August 2023). "Structure-Activity Assessment and In-Depth Analysis of Biased Agonism in a Set of Phenylalkylamine 5-HT2A Receptor Agonists". ACS Chem Neurosci.
24. (September 2005). "Hallucinogen-like actions of 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7) in mice and rats". Psychopharmacology.
25. (2011). "[[The Shulgin Index, Volume One: Psychedelic Phenethylamines and Related Compounds]]". [[Transform Press]].
26. (1 July 1990). "Treatment of alcoholism". Journal of Psychoactive Drugs.
27. (January 1991). "Central nervous system (CNS) activity of two new psychoactive compounds". Journal of Psychoactive Drugs.
28. (May 1, 2002). "2C-T-7's Bad Trip". East Bay Express.
29. (2016-05-04). "Canada Gazette – Regulations Amending the Food and Drug Regulations (Part J — 2C-phenethylamines)". Government of Canada, Public Works and Government Services Canada, Public Services and Procurement Canada, Integrated Services Branch, Canada.
30. (27 September 2015). "关于印发《非药用类麻醉药品和精神药品列管办法》的通知". China Food and Drug Administration.
31. "Valtioneuvoston asetus huumausaineina pidettävistä aineista, valmisteista ja kasveista | 543/2008 | Lainsäädäntö | Finlex".
32. "Läkemedelsverkets författningssamling".
33. "Förordning (1999:58) om förbud mot vissa hälsofarliga varor - Karnov Open".
34. "2C-T-7 Fast Facts". U.S. [[United States Department of Justice.
35. "List of Schedule 1 drugs on the DEA Office of Diversion Control website".
36. "2,5-DIMETHOXY-4-(n)-PROPYLTHIOPHENETHYLAMINE (Street Names: 2C-T-7, Blue Mystic, T7, Beautiful, Tripstay, Tweety-Bird Mescaline)".